Join
Live feed
·
INSIDERFilingvia Quantisnow
Apellis Pharmaceuticals Inc. logo

Chief Research and Development Meltzer Leslie returned 174,854 shares to the company and was granted 67,830 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax

ByQuantisnow·Wall Street's wire, on your screen.
APLS· Apellis Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APLS (Apellis Pharmaceuticals Inc.) and more on Quantisnow.